Neuraxis Inc
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Neuraxis Inc's stock with a target price of $7.50, indicating strong growth potential.
Financial Health
Neuraxis Inc shows moderate revenue and cash flow, but its low book value raises concerns.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NRXS
Brain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap dynamics
A modest market cap can mean higher growth potential but also greater volatility and limited liquidity; suitability depends on your risk tolerance.
Innovation and regulation
If the company develops medical technologies, innovation and regulatory approvals are central value drivers — clinical outcomes and approvals can change prospects quickly.
Research checklist
Look for clinical data, cash runway, partnerships and recent filings; remember past performance doesn’t guarantee future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
